Urovant Sciences® Announces Partnership with Thinx Inc. to Help Americans with Overactive Bladder This Travel Season

Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., announced the launch of Time To GoTM today, a multi-channel educational camp

Digital health news, funding round up in the prior week; November 21, 2022

Endpoints News — Genentech touts Tecentriq combo data in liver cancer; Rep. Frank Pallone criticizes noncompliance with trial records law

ICS 2022 Abstract #6 Efficacy and Safety of a Novel Gene Therapy (URO-902; pVAX/hSlo) in Female Patients With Overactive Bladder Syndrome and Urgency Urinary Incontinence: Results From a Phase 2a Trial

Vibrant America Total Tox Burden -Urine Sample – Dr Jaban Moore - Store

Overactive Bladder Urology - Top Urologist NYC

Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women's Health

Translating Policy into Practice: Sexual Violence Policies and the University

Urovant Sciences® Announces Partnership with Thinx Inc. to Help Americans with Overactive Bladder This Travel Season

EHR vendors don't have to draw a 'line in the sand' on reproductive data privacy

Bill banning puberty blockers, hormone treatments for trans kids sent to Texas governor

Welcome to Urovant Sciences Medical Affairs

Contact Us Battle River Treaty 6 Health Centre